Wealthcare Advisory Partners LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating) by 4.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 682 shares of the medical research company stock after purchasing an additional 26 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Thermo Fisher Scientific were worth $ 403,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Widmann Financial Services Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $ 26,000. Mystic Asset Management Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $ 29,000. Lee Financial Co acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $ 32,000. Costello Asset Management INC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $ 33,000. Finally, Sumitomo Mitsui Financial Group Inc. lifted its stake in Thermo Fisher Scientific by 141.7% during the 4th quarter. Sumitomo Mitsui Financial Group Inc. now owns 58 shares of the medical research company stock valued at $ 38,000 after acquiring an additional 34 shares during the period. Institutional investors and hedge funds own 87.48% of the company stock.
In related news, CEO Marc N. Casper sold 10,000 shares of the company stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $ 545.60, for a total value of $ 5,456,000.00. Following the completion of the sale, the chief executive officer now owns 183,373 shares of the company stock, valued at $ 100,048,308.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michel Lagarde sold 13,030 shares of the company stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $ 565.04, for a total transaction of $ 7,362,471.20. Following the completion of the transaction, the chief operating officer now directly owns 15,758 shares in the company, valued at approximately $ 8,903,900.32. The disclosure for this sale can be found here. Insiders have sold 42,561 shares of company stock valued at $ 23,557,413 in the last ninety days. Insiders own 0.43% of the company stock.
Thermo Fisher Scientific stock opened at $ 535.77 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $ 497.83 and a 52-week high of $ 672.34. The firm has a market capitalization of $ 209.73 billion, a price-to-earnings ratio of 27.93, a PEG ratio of 1.85 and a beta of 0.83. The company has a fifty day simple moving average of $ 541.93 and a 200-day simple moving average of $ 572.26. The company has a quick ratio of 1.10, a current ratio of 1.56 and a debt-to-equity ratio of 0.77.
Thermo Fisher Scientific (NYSE: TMO – Get Rating) last released its earnings results on Thursday, April 28th. The medical research company reported $ 7.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $ 6.17 by $ 1.08. Thermo Fisher Scientific had a net margin of 18.49% and a return on equity of 25.33%. The business had revenue of $ 11.82 billion during the quarter, compared to analyst estimates of $ 10.66 billion. During the same quarter in the prior year, the firm earned $ 7.21 earnings per share. The company revenue for the quarter was up 19.3% compared to the same quarter last year. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Stockholders of record on Wednesday, June 15th will be issued a dividend of $ 0.30 per share. This represents a $ 1.20 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend is Tuesday, June 14th. Thermo Fisher Scientific’s payout ratio is 6.26%.
Several equities analysts recently issued reports on TMO shares. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $ 605.00 to $ 525.00 in a research note on Monday, April 25th. StockNews.com started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $ 658.92.
About Thermo Fisher Scientific: (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE: TMO – Get Rating).
Receive News & Ratings for Thermo Fisher Scientific Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.